Literature DB >> 19515472

Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment.

Richard D Swartz1.   

Abstract

Idiopathic retroperitoneal fibrosis (IRPF) is an increasingly recognized syndrome. The development of inflammation and fibrosis in the retroperitoneum most often results in a periaortic mass on computed tomography or magnetic resonance imaging that causes pain and constitutional symptoms. Its organ involvement results in urinary tract obstruction, bowel dysfunction, and venous compression with leg swelling, or thrombosis. The syndrome appears autoimmune in nature, but has no specific immunologic markers. However, nonspecific inflammatory indicators, such as sedimentation rate and C-reactive protein level, reflect disease activity and therapeutic response. Retroperitoneal fibrosis also can arise secondary to inflammatory, infectious, or malignant disease in retroperitoneal organs, in which case treatment is directed at the primary process. However, in patients with IRPF, initial treatment of the local mechanical complications must be followed by medical therapy with corticosteroids or, more recently, the addition of steroid-sparing agents. Although there are no controlled therapeutic trials, a number of reports with as few as 3 or as many as 28 cases describe sustained and effective steroid-sparing treatment with cyclophosphamide, azathioprine or colchicine, or such newer agents as mycophenolate mofetil or tamoxifen. Overall, IRPF responds to corticosteroid therapy initially but recurs without prolonged treatment. Sustained remission can be attained with steroid-sparing treatment. Kidney function can be preserved, and local organ dysfunction can remit for periods of 10 years or more. Although not randomized or controlled, the evidence convincingly supports a combination of initial surgical or urological intervention, along with early corticosteroid therapy for up to 6 months followed by either mycophenolate or tamoxifen for 1 to 3 years. What was previously believed to be an uncommon and challenging syndrome can be treated successfully when recognized by its characteristic presentation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515472     DOI: 10.1053/j.ajkd.2009.04.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

1.  [¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience.

Authors:  Francesco Bertagna; Giorgio Treglia; Lucia Leccisotti; Giovanni Bosio; Federica Motta; Alessandro Giordano; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2012-03-16       Impact factor: 2.374

Review 2.  [Diagnosis and treatment of retroperitoneal fibrosis].

Authors:  A S Brandt; S Kukuk; N M Dreger; E Müller; S Roth
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

Review 3.  Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease.

Authors:  Giovanni Maria Rossi; Rossana Rocco; Eugenia Accorsi Buttini; Chiara Marvisi; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-01-09       Impact factor: 3.397

Review 4.  [Chronic periaortitis].

Authors:  J H Schirmer; M Both; F Moosig
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

5.  Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes.

Authors:  Tanaz A Kermani; Cynthia S Crowson; Sara J Achenbach; Harvinder S Luthra
Journal:  Mayo Clin Proc       Date:  2011-04       Impact factor: 7.616

6.  Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis.

Authors:  Mryanda Sopel; Alec Falkenham; Adam Oxner; Irene Ma; Timothy D G Lee; Jean-Francois Légaré
Journal:  Int J Exp Pathol       Date:  2012-01-07       Impact factor: 1.925

7.  [Therapy of retroperitoneal fibrosis: functional therapeutic outcome].

Authors:  A S Brandt; S Kukuk; N M Dreger; E Müller; S Roth
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

8.  High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation.

Authors:  Michael Rehman; Simone Vodret; Luca Braga; Corrado Guarnaccia; Fulvio Celsi; Giulia Rossetti; Valentina Martinelli; Tiziana Battini; Carlin Long; Kristina Vukusic; Tea Kocijan; Chiara Collesi; Nadja Ring; Natasa Skoko; Mauro Giacca; Giannino Del Sal; Marco Confalonieri; Marcello Raspa; Alessandro Marcello; Michael P Myers; Sergio Crovella; Paolo Carloni; Serena Zacchigna
Journal:  JCI Insight       Date:  2019-04-18

Review 9.  Desmoid tumors: clinical features and treatment options for advanced disease.

Authors:  Bernd Kasper; Philipp Ströbel; Peter Hohenberger
Journal:  Oncologist       Date:  2011-04-08

10.  Ureteric obstruction secondary to retroperitoneal fibrosis leading to acute kidney injury.

Authors:  Harald Bjorndalen; Robert A Hastings
Journal:  BMJ Case Rep       Date:  2013-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.